Scientific Presentations & Publications

33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat patients with NSCLC harboring osimertinib-resistant mutations with or without brain metastases

Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers

Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers


2021 American Society of Clinical Oncology Annual Meeting

Safety and Preliminary Efficacy From the Phase 1 Portion of MasterKey-01: A First-in-Human Dose-Escalation Study to Determine the Recommended Phase 2 Dose, Pharmacokinetics and Preliminary Antitumor Activity of BDTX-189, an Inhibitor of Allosteric EGFR/HER2 Mutations, in Patients With Advanced Solid Malignancies

Clinical Pharmacokinetics of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients With Advanced Solid Malignancies in MasterKey-01 Study


American Association for Cancer Research Annual Meeting 2021

Prospective Preclinical Modeling to Estimate Clinical Pharmacokinetics and Dose of BDTX-189, an Inhibitor of Allosteric ErbB Mutations in Advanced Solid Malignancies

CNS Penetrant, Irreversible Inhibitors Potently Inhibit the Family of Allosteric Oncogenic EGFR Mutants Expressed in GBM and Demonstrate Efficacy in Patient-Derived Xenograft Models


European Society of Medical Oncology Targeted Anticancer Therapies Virtual Congress 2021

Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers

Pre-clinical evaluation of a potent and orally bioavailable next-generation inhibitor targeting the family of mutants that drive oncogenic BRAF dimer formation


Society for Neuro-Oncology’s 25th Annual Meeting and Education Day

Potent, selective, and brain penetrant inhibitors of extracellular domain EGFR oncogenic mutants expressed in GBM demonstrate efficacy in an intracranial patient derived xenograft model


32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020)

BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations


American Society of Clinical Oncology (ASCO) 2020

Abstract TPS3665: Masterkey-01: Phase 1/2, Open-label Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients with Advanced Solid Malignancies


bioRxiv

EGFR Oncogenes Expressed in Glioblastoma are Activated as Covalent Dimers and Paradoxically Stimulated by Erlotinib


European Society of Medical Oncology (ESMO) 2019

Oncogenic Mutations at the Dimer Interface of EGFR Lead to Formation of Covalent Homo-Dimers and Allosteric Activation of the Kinase Domain: A Mechanism Which Alters the Selectivity Profile of Oncogenic EGFR


American Association for Cancer Research (AACR) 2019

Epidermal Growth Factor Receptor Oncogenes Expressed in Glioblastoma are Activated as Covalent Dimers and Exhibit Unique Pharmacology